ClinicalTrials.gg
CompletedNCT03350217Updated Dec 17, 2019Results posted

A Comparison of Eleview Versus Hetastarch as Injectate for EMR

A Phase 4 interventional study of Eleview and Hetastarch in Procedural Bleeding, Delayed Bleeding and Post-Polypectomy Syndrome, sponsored by Indiana University. Completed at 1 site in United States. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2019-12-17.

Sponsored by Indiana University · Phase 4, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
160
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

EMR is a technique used for the removal of flat or sessile neoplasms confined to the superficial layers of the GI tract using a snare. Injection-assisted EMR is commonly used during resections of larger flat lesions as it provides submucosal lift of polyps, adenomas, other gastrointestinal mucosal lesions or early-stage cancers prior to EMR. This has been found to minimize mechanical or electrocautery damage to the deep layers of the gastrointestinal tract wall as the injectate provides a "safety cushion" as such between the area to be removed and healthy mucosal tissue.

Several solutions are used today for injecting lesions including saline, hyaluronic acid, and hydroxyethyl starch (Hetastarch). Saline solution has been found to dissipate within minutes, which may result in a lower quality lesion lift. Hyaluronic acid provides a longer lift, but is expensive and is not readily available in the U.S.

A new injectate known as Eleview has been developed for use in gastrointestinal endoscopic procedures and recently approved by the FDA. This injectate boasts a cushion of excellent height and duration through the use of an oil-in-water emulsion. However, the initial cost of this material is quite high ($80 per 10 ml).

Hetastarch, which is the current injectate used by Dr Rex, is a safe and considerably inexpensive solution that provides prolonged submucosal elevation and lowers procedure times. Our study will aim to compare Eleview to Hetastarch in the hopes of finding the ideal submucosal injectate.

This trial will focus on polyps of size ≥11 mm removed by snare EMR technique. Patients with lesions deemed not suitable for EMR due to features suggestive of sub-mucosal invasion will not be included.

Read the detailed description

Injectate randomization:

Study patients will be randomly assigned to the Eleview or the Hetastarch treatment group in a 1:1 ratio. Randomization will occur at the site using envelopes provided by the Investigator. The envelope's contents will specify the treatment assignment for each patient and opened by the research team (PI will be blinded). The investigators will monitor the safety and effectiveness data. The appropriate solutions will be injected into the submucosal space beneath the lesion(s) to be excised before the lesion(s) is/are removed. Subjects in both groups will receive the appropriate volume of injectate deemed necessary by the PI for the individual patient.

Sample size and Statistical Analysis At least 200 patients will be enrolled. 100 of these patients will be randomized to Eleview injectate and 100 will be given the standard of care, Hetastarch injectate only. Efficacy and safety of Eleview injectate has only been reviewed in one previous study. Therefore, the planned sample size was not calculated using a statistical power analysis, but was regarded as sufficient to repeat the objectives of the COSMO study (2017) and satisfy the exploratory purposes of the present study.

Study personnel will carry out a simple randomization using a commonly used online generator. Randomization assignments will then be sealed until day of procedure until patient eligibility has been confirmed. The Principal Investigator will remain blinded and will perform all data analysis after completion of the study.

Data will be summarized and compared using classic descriptive statistics, i.e. mean, standard deviation, coefficient of variation (%), minimum, median and maximum values for quantitative variables, and frequencies for qualitative variables.

The Sydney Resection Quotient will be compared between treatment groups using a Wilcoxon Rank-Sum test. The proportion of subjects with en bloc resection of all endoscopically visible lesions will also be compared between treatment groups using a Fisher's exact test. A nominal alpha level of 0.05 will be used for both the comparisons.

No formal comparison will be performed for the secondary endpoints.

02

Conditions studied

  • Procedural Bleeding
  • Delayed Bleeding
  • Post-Polypectomy Syndrome
  • Post Procedural Complication
03

In context

Lead sponsor

Indiana University is the lead sponsor of 990 studies on the registry; 201 are open to participants now.

Of its 150 completed or terminated interventional studies of FDA-regulated products, 118 (79%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Sex and age: men and women > 18 years old
  2. Subjects referred for EMR of polyps of size ≥11 mm
  3. 1, 2 or 3.
  4. : Women of must have a negative pregnancy test (one is provided as the standard of care) or sign a waiver. women must have been in that status for at least 1 year (per standard of care).
  5. Subject is willing and able to participate in the study procedures and to understand and sign the

Exclusion criteria

Exclusion Criteria:

  1. Age: Subjects is under 18 years old
  2. Consent: Vulnerable subjects including those who are unable to consent
  3. Pregnancy: Pregnant or breastfeeding women
  4. \<3
  5. Physical findings: Abnormal physical findings that may interfere with the study objectives
  6. Study participation: Subjects currently participating in another clinical study or previously enrolled in another clinical study in the last 30 days
  7. Excluded lesions:

    • Lesions less than 11 mm in largest dimension
    • Lesions involving the muscularis propria (T2 lesions)
    • Ulcerated depressed lesions (Paris type III) or pathology proven invasive carcinoma
    • Proven malignant disease locally advanced or with
    • Active inflammatory bowel disease lesion, e.g ulcerative colitis, Crohn's disease
    • Endoscopic appearance of invasive
  8. Previous partial resection or attempted resection of the lesion
  9. Allergy: Proven or potential allergic reaction to study products or history of anaphylaxis to drugs
  10. Severe liver disease.
  11. Known or suspected gastrointestinal obstruction or perforation, active diverticulitis, toxic megacolon,
  12. Inflammatory bowel disease e.g ulcerative colitis or Crohn's disease
  13. Hemostasis disorders (eg Von Willebrand disease, factor V Leiden thrombophilia or haemophilia), known clotting disorder (>1.5).
  14. Subject with any other current serious medical conditions that would increase the risks associated with taking part in the study.
  15. Patients must be advised to stop anticoagulation medications prior to the procedure per local practice guidelines and should re-start as clinically indicated after the procedure.
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ASA physical status

The anaesthetists’ scale of health before surgery: I is healthy, II has a mild illness that is under control, III a severe one, IV a severe illness that is a constant threat to life. V and VI are used for the critically ill and for organ donors.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Investigator)
Enrollment
160 participants (actual)

Study arms

  • Active comparator
    Eleview

    This arm will be administered the Eleview Injectate (up to 50 mL's) solution upon randomization, provided the lesion is equal to or greater than 11 millimeters.

    Drug: Eleview

  • Active comparator
    Hetastarch

    This arm will be administered Hetastarch (w/Methylene blue as a contrast agent) as the injection solution upon randomization, provided the lesion is equal to or greater than 11 millimeters.

    Drug: Hetastarch

Interventions

  • DrugEleview

    If a lesion in the colon is found to fit the description listed in the protocol, the subject will be randomized to Eleview or Hetastarch as the injectate solution for the procedure. The injectate solution is used, as needed, to aid in the resection of the target lesion.

  • DrugHydroxyethyl Starch DerivativesStudies of Hydroxyethyl Starch DerivativesHydroxyethyl Starch Derivatives pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    If a lesion in the colon is found to fit the description listed in the protocol, the subject will be randomized to Eleview or Hetastarch as the injectate solution for the procedure. The injectate solution is used, as needed, to aid in the resection of the target lesion.

    Also known as: Hespan

06

What researchers measure

Primary outcomes

  1. Sydney Resection Quotient (SRQ)

    Comparison of the Sydney Resection Quotient between EMRs done using Eleview vs EMRs done using Hetastartch as the injection fluid. The Sydney Resection Quotient (SRQ) is the size of the polyp divided by the number of pieces in which the polyp was resected. A larger SRQ is better than a smaller SRQ.

    Time frame: During the large polyp removal

Secondary outcomes

  1. Injected Volume Needed for Initial Lesion Lift

    Comparison of the volume of injection fluid needed for initial lesion lift of Eleview vs Hetastarch.

    Time frame: During initial injection portion of large polyp removal

  2. Injected Volume Needed for Complete Removal of Lesion

    Comparison of the volume of injection fluid needed for complete removal of lesion between Eleview and Hetastarch

    Time frame: During the large polyp removal

  3. Number of Re-injections Needed During Resection

    Comparison of the number of re-injections needed during the large polyp removal. Number of re-injections is the number of times the injection device is passed down the scope to inject the polyp after initial injection during the large polyp resection.

    Time frame: During the large polyp removal

  4. Number of En Bloc Resections

    Comparison of the number of polyps that were able to be removed in one piece during the resection between polyps injected with Eleview and polyps injected with Hetastarch

    Time frame: During the large polyp removal

  5. Number of Pieces Resected Using Snares

    Comparison of the number of pieces removed using snare between polyps injected with Eleview compared with polyps injected with Hetastarch.

    Time frame: During the large polyp removal

  6. Mound Concentration Diameter

    Comparison fluid behavior and ease of use between Eleview and Hetastarch rated on a 3-point scale (Excellent, Sufficient, or Inadequate). The more the fluid spread out laterally after being injected, the worse the rating would be. The more the fluid stayed concentrated around the polyp after injection, the better the rating would be.

    Time frame: During the large polyp removal

  7. Mound Concentration Height

    Comparison of how well the injection fluid lifted the polyp during the large polyp removal between Eleview and Hetastarch rated by the following scale: Excellent, Sufficient, Inadequate. The more the polyp was able to be lifted vertically, the better the rating would be.

    Time frame: During the large polyp removal

  8. Mound Duration

    Comparison of how long the injection fluid was able to keep the polyp lifted during the large polyp removal between Eleview and Hetastarch. This was rating using the following scale: Excellent, Sufficient, or Inadequate. The longer the injection fluid stayed concentrated and kept the polyp lifted, the better rating it received while rapid dissipation of the fluid would receive a worse rating.

    Time frame: During the large polyp removal

  9. Ease of Injection

    Comparison of how easily the fluid was able to be injected. This was rated by the endoscopy technician assisting in the large polyp removal. It was rated on the following scale: Very Easy, Easy, Difficult, Very Difficult.

    Time frame: During the large polyp removal

  10. Need for Additional Treatments Relating to the Polyp Resection Such as Avulsion, Coagulation or Ablation.

    Need for additional treatments relating to the polyp resection such as avulsion, coagulation or ablation. These treatments can be done in addition to endoscopic mucosal resection (EMR) in order to remove polyp tissue/treat the defect.

    Time frame: During the large polyp removal

  11. Time Required to Remove the Lesion

    Time (in minutes) to remove the lesion completely (measured from the first injection to final excision of the lesion)

    Time frame: During the large polyp removal

  12. Safety Outcomes as Assessed by Complications During or After the Procedure

    To evaluate the safety of Eleview for EMR procedures in relation to adverse events and occurrence of complications during and after the EMR procedure in comparison to Hetastarch injectate.

    Time frame: during large polyp removal through 30 days post procedure

07

Results

Posted Dec 17, 2019
Limitations and caveats
limitations include single-center, single-endoscopist design which could limit the generalizability.

Participant flow

Participant flow — Overall Study
MilestoneEleviewHetastarch
Started7981
Completed7781
Not completed20

Outcome measures

PrimarySydney Resection Quotient (SRQ)

Comparison of the Sydney Resection Quotient between EMRs done using Eleview vs EMRs done using Hetastartch as the injection fluid. The Sydney Resection Quotient (SRQ) is the size of the polyp divided by the number of pieces in which the polyp was resected. A larger SRQ is better than a smaller SRQ.

Time frame:
During the large polyp removal
Reported as:
Mean · Ratio
Sydney Resection Quotient (SRQ)
RatioEleviewHetastarch
Adenomas9.3 ± 6.28.1 ± 4.9
Serrated12.3 ± 4.011.1 ± 6.5
SecondaryInjected Volume Needed for Initial Lesion Lift

Comparison of the volume of injection fluid needed for initial lesion lift of Eleview vs Hetastarch.

Time frame:
During initial injection portion of large polyp removal
Reported as:
Mean · milliliters
Injected Volume Needed for Initial Lesion Lift
millilitersEleviewHetastarch
Adenomas10.4 ± 5.411.6 ± 7
Serrated7.1 ± 4.98.7 ± 4.3
SecondaryInjected Volume Needed for Complete Removal of Lesion

Comparison of the volume of injection fluid needed for complete removal of lesion between Eleview and Hetastarch

Time frame:
During the large polyp removal
Reported as:
Mean · milliliters
Injected Volume Needed for Complete Removal of Lesion
millilitersEleviewHetastarch
Adenomas14.8 ± 13.120.6 ± 20.9
Serrated Lesions7.8 ± 5.710.7 ± 8.8
SecondaryNumber of Re-injections Needed During Resection

Comparison of the number of re-injections needed during the large polyp removal. Number of re-injections is the number of times the injection device is passed down the scope to inject the polyp after initial injection during the large polyp resection.

Time frame:
During the large polyp removal
Reported as:
Mean · reinjections
Number of Re-injections Needed During Resection
reinjectionsEleviewHetastarch
Adenomas0.61 ± 1.31.01 ± 1.6
Serrated Lesions0.1 ± 0.310.3 ± 0.9
SecondaryNumber of En Bloc Resections

Comparison of the number of polyps that were able to be removed in one piece during the resection between polyps injected with Eleview and polyps injected with Hetastarch

Time frame:
During the large polyp removal
Reported as:
Number · Polyps
Number of En Bloc Resections
PolypsEleviewHetastarch
Adenomas1814
Serrated Lesions22
SecondaryNumber of Pieces Resected Using Snares

Comparison of the number of pieces removed using snare between polyps injected with Eleview compared with polyps injected with Hetastarch.

Time frame:
During the large polyp removal
Reported as:
Mean · polyp pieces resected
Number of Pieces Resected Using Snares
polyp pieces resectedEleviewHetastarch
Adenomas4.5 ± 55.5 ± 5.3
Serrated Lesions7 ± 5.98.2 ± 7
SecondaryMound Concentration Diameter

Comparison fluid behavior and ease of use between Eleview and Hetastarch rated on a 3-point scale (Excellent, Sufficient, or Inadequate). The more the fluid spread out laterally after being injected, the worse the rating would be. The more the fluid stayed concentrated around the polyp after injection, the better the rating would be.

Time frame:
During the large polyp removal
Reported as:
Number · Polyps
Mound Concentration Diameter
PolypsEleviewHetastarch
Excellent6454
Sufficient4141
Inadequate97
SecondaryMound Concentration Height

Comparison of how well the injection fluid lifted the polyp during the large polyp removal between Eleview and Hetastarch rated by the following scale: Excellent, Sufficient, Inadequate. The more the polyp was able to be lifted vertically, the better the rating would be.

Time frame:
During the large polyp removal
Reported as:
Number · Polyps
Mound Concentration Height
PolypsEleviewHetastarch
Excellent6758
Sufficient3738
Inadequate106
SecondaryMound Duration

Comparison of how long the injection fluid was able to keep the polyp lifted during the large polyp removal between Eleview and Hetastarch. This was rating using the following scale: Excellent, Sufficient, or Inadequate. The longer the injection fluid stayed concentrated and kept the polyp lifted, the better rating it received while rapid dissipation of the fluid would receive a worse rating.

Time frame:
During the large polyp removal
Reported as:
Number · Polyps
Mound Duration
PolypsEleviewHetastarch
Excellent6058
Sufficient4139
Inadequate115
Unknown20
SecondaryEase of Injection

Comparison of how easily the fluid was able to be injected. This was rated by the endoscopy technician assisting in the large polyp removal. It was rated on the following scale: Very Easy, Easy, Difficult, Very Difficult.

Time frame:
During the large polyp removal
Reported as:
Number · Polyps
Ease of Injection
PolypsEleviewHetastarch
Very easy5246
Easy5852
Difficult33
Very difficult00
Unknown11
SecondaryNeed for Additional Treatments Relating to the Polyp Resection Such as Avulsion, Coagulation or Ablation.

Need for additional treatments relating to the polyp resection such as avulsion, coagulation or ablation. These treatments can be done in addition to endoscopic mucosal resection (EMR) in order to remove polyp tissue/treat the defect.

Time frame:
During the large polyp removal
Reported as:
Number · Polyps requiring additional treatments
Need for Additional Treatments Relating to the Polyp Resection Such as Avulsion, Coagulation or Ablation.
Polyps requiring additional treatmentsEleviewHetastarch
avulsion3736
soft coagulation7255
ablation97
SecondaryTime Required to Remove the Lesion

Time (in minutes) to remove the lesion completely (measured from the first injection to final excision of the lesion)

Time frame:
During the large polyp removal
Reported as:
Mean · minutes
Time Required to Remove the Lesion
minutesEleviewHetastarch
Adenomas14.8 ± 11.416.02 ± 13.9
Serrated Lesions5.9 ± 4.27.1 ± 9.1
SecondarySafety Outcomes as Assessed by Complications During or After the Procedure

To evaluate the safety of Eleview for EMR procedures in relation to adverse events and occurrence of complications during and after the EMR procedure in comparison to Hetastarch injectate.

Time frame:
during large polyp removal through 30 days post procedure
Reported as:
Number · Polyps
Safety Outcomes as Assessed by Complications During or After the Procedure
PolypsEleviewHetastarch
Intraprocedural bleeding1814
Delayed Bleeding11
Post procedure abdonimal pain01
Perforation10

Adverse events

Collected over 1 month. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Eleview0/77 (0%)0/77 (0%)16/77 (20.8%)
Hetastarch0/81 (0%)0/81 (0%)15/81 (18.5%)
Most frequent other events
Most frequent other events
EventEleviewHetastarch
Intraprocedural BleedingInjury, poisoning and procedural complications14/7713/81
Delayed BleedInjury, poisoning and procedural complications1/771/81
Type 3 Deep Mural InjuryInjury, poisoning and procedural complications1/770/81
Abdominal PainInjury, poisoning and procedural complications0/771/81

Baseline characteristics

Age, Continuous
Age, Continuous(Years)EleviewHetastarchTotal
Mean67.2 ± 8.365.6 ± 10.366.4 ± 9.4
Sex: Female, Male
Sex: Female, Male(Participants)EleviewHetastarchTotal
Female433982
Male344276
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)EleviewHetastarchTotal
Black or African American101
White5264116
Unknown241741
Region of Enrollment
Region of Enrollment(participants)EleviewHetastarchTotal
United States7781158
Number of lesions randomized in the study
Number of lesions randomized in the study(Lesions)EleviewHetastarchTotal
Number114102159
08

Study locations

1 site
  • Indiana University
    Indianapolis, Indiana 46202, United States
09

References and documents

Publications

  • Fasoulas K, Lazaraki G, Chatzimavroudis G, Paroutoglou G, Katsinelos T, Dimou E, Geros C, Zavos C, Kountouras J, Katsinelos P. Endoscopic mucosal resection of giant laterally spreading tumors with submucosal injection of hydroxyethyl starch: comparative study with normal saline solution. Surg Laparosc Endosc Percutan Tech. 2012 Jun;22(3):272-8. doi: 10.1097/SLE.0b013e318251553c. PubMed 22678327 ↗
  • ASGE Technology Committee; Liu J, Petersen BT, Tierney WM, Chuttani R, Disario JA, Coffie JM, Mishkin DS, Shah RJ, Somogyi L, Song LM. Endoscopic banding devices. Gastrointest Endosc. 2008 Aug;68(2):217-21. doi: 10.1016/j.gie.2008.03.1121. No abstract available. Erratum In: Gastrointest Endosc. 2009 Jan;69(1):193. PubMed 18656592 ↗
  • ASGE Technology Committee; Hwang JH, Konda V, Abu Dayyeh BK, Chauhan SS, Enestvedt BK, Fujii-Lau LL, Komanduri S, Maple JT, Murad FM, Pannala R, Thosani NC, Banerjee S. Endoscopic mucosal resection. Gastrointest Endosc. 2015 Aug;82(2):215-26. doi: 10.1016/j.gie.2015.05.001. Epub 2015 Jun 12. PubMed 26077453 ↗
  • Rex DK, Broadley HM, Garcia JR, Lahr RE, MacPhail ME, McWhinney CD, Searight MP, Sullivan AW, Mahajan N, Eckert GJ, Vemulapalli KC. SIC-8000 versus hetastarch as a submucosal injection fluid for EMR: a randomized controlled trial. Gastrointest Endosc. 2019 Nov;90(5):807-812. doi: 10.1016/j.gie.2019.06.040. Epub 2019 Jul 6. PubMed 31288028 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Oct 2017 to primary completion in Jan 2019, 14 months.

Results were first posted in Dec 2019, 11 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 19, 2017
First posted
Nov 22, 2017
StartActual
Oct 9, 2017
Primary completionActual
Jan 7, 2019
CompletionActual
Jan 7, 2019
Results first posted
Dec 17, 2019
Last update
Dec 17, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 17, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03350217
Lead sponsor
Indiana University
Responsible party
Douglas K. Rex (Endoscopy Chief, Indiana University) — Principal investigator
First posted
Nov 22, 2017
Start date
Oct 9, 2017
Primary completion
Jan 7, 2019
Completion
Jan 7, 2019
Results posted
Dec 17, 2019
Last update
Dec 17, 2019

Study contacts

Douglas Rex
principal investigator · Indiana University

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Hydroxyethyl Starch Derivatives

Start the discussion